Answers are grounded in this paper and cite their sources.
Tumor radiotherapy is one of the core modalities in comprehensive clinical cancer treatment. However, the inherent radiation resistance of tumor cells, radiotherapy resistance mediated by the tumor microenvironment, and irreversible damage to normal tissues caused by radiotherapy severely limit its clinical efficacy. Although various radiosensitizers have been developed to enhance radiation-induced tumor damage, their clinical translation largely depends on efficient and tumor-specific delivery systems. This review first summarizes the biological basis of radiosensitization and the major classes of radiosensitizers and then focuses on recent advances in biomimetic delivery platforms designed to improve tumor targeting, microenvironment modulation, and immune activation. Collectively, cell membrane-coated biomimetic nanoplatforms represent a promising strategy for integrating precise radiosensitizer delivery with tumor microenvironment modulation to enhance radiotherapy efficacy. Future work should be dedicated to optimizing membrane engineering, designing multifunctional nanoparticles, and developing manufacturing strategies for clinical translation, thereby accelerating their implementation in precision radiotherapy.
No takes yet. Share an insight, caveat, or question.
Cao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: